Viral immunogenic compositions

Abstract

Disclosed herein are immunogenic compositions for producing immediate and sustained immunity to infectious viral and bacteriological pathogens. A univalent immunogenic composition is disclosed comprising an isolated antigen and a polynucleotide formulated into a nanoparticle or liposome. Furthermore, multivalent immunogenic compositions are disclosed comprising multiple univalent immunogenic compositions. Also disclosed, are methods of inducing protective or therapeutic immune responses in individuals comprising administering one or more univalent immunogenic compositions.

What is claimed is: 
     
       1. A method of vaccination for influenza A virus by preparing two discrete liposomal vaccines; and concurrently vaccinating each person exposed to viral infection with said discrete liposomal vaccines wherein:
 (i) the first liposomal vaccine is composed of a purified recombinant hemagglutinin (H) antigen sub-type corresponding to the H antigenic sub-type of the identified virus strain, combined with either poly IC or poly ICLC within a liposome; and wherein monophosphoryl lipid A is optionally incorporated in the lipid layer of the liposome and 
 (ii) the second liposomal vaccine is composed of a purified recombinant neuraminidase (N) antigen sub-type corresponding to the N antigenic sub-type of the identified virus strain, combined with either poly IC or poly ICLC within a liposome; and wherein monophosphoryl lipid A is optionally incorporated in the lipid layer of the liposome and 
 (iii) all the components required to prepare each of the first and second vaccines were made beforehand and stockpiled to enable the rapid preparation of each vaccine; and wherein said vaccine components included a panel of recombinant H antigen subtypes; a panel of recombinant N antigen subtypes; Poly IC; Poly ICLC; monophosphoryl lipid A, cholesterol, and one or more phospholipids selected from a list of: phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, phosphatidylinositol, monosialoganglioside, sphingomyelin, distearoylphosphatidylethanolamine, distearoylphosphatidylcholine, dimyristoylphosphatidylcholine, dimyristoylphosphatidylglycerol and dipalmitoylphosphatidylcholine. 
 
     
     
       2. A method of vaccination for influenza A virus according to  claim 1  wherein the method of administering each of the two discrete liposomal vaccines disclosed in  claim 1  is selected from the group consisting of scarification, intradermal injection, and intramuscular injection, and wherein the H antigen sub-type vaccine is administered at a different anatomical location from the N antigen sub-type vaccine either in separate sites on the same arm, or administering one vaccine in one arm and the other vaccine in the other arm.